Roivant details Phase 2 PHocus data for mosliciguat, unveils ongoing Phase 3 PHrontier trial
Roivant presented full PHocus results at ERS 2026 and confirmed its Phase 3 PHrontier study in PH-ILD is now enrolling patients.
SEC filing
Latest
4 stories
Tuesday, September 8
Friday, August 28
FDA approves Roivant's LISRAYA for dermatomyositis, launch begins immediately
The once-daily TYK2/JAK1 inhibitor becomes the first targeted therapy approved for the rare autoimmune disease, with commercial availability starting ahead of prior guidance.
SEC filing (2)
Thursday, August 6
Roivant reports Q1 fiscal 2027 results, pipeline on track across four vants
Roivant said brepocitinib launch prep for dermatomyositis remains on schedule, three trial readouts are due in the second half of 2026, and it holds $3.9 billion in cash and securities.
SEC filing
Immunovant reports Q1 fiscal 2026 results, says IMVT-1402 timelines on track
The company reported cash of $797.8 million as of June 30, 2026, and said all six IMVT-1402 disease programs remain on schedule.
SEC filing